MRNS - MARINUS PHARMACEUTICALS, INC.
IEX Last Trade
0.3625
-0.003 -0.745%
Share volume: 10,188
Last Updated: Fri 27 Dec 2024 08:27:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.37
0.00
-0.74%
Fundamental analysis
32%
Profitability
25%
Dept financing
30%
Liquidity
75%
Performance
30%
Performance
5 Days
35.63%
1 Month
-0.62%
3 Months
-82.46%
6 Months
-73.76%
1 Year
-97.06%
2 Year
-90.93%
Key data
Stock price
$0.36
DAY RANGE
$0.31 - $0.37
52 WEEK RANGE
$0.24 - $11.26
52 WEEK CHANGE
-$97.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Scott N. Braunstein
Region: US
Website: marinuspharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: marinuspharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.
Recent news